Total Page Views

Saturday, January 1, 2011

Top Health News 2010

2010 was an eventful year for health-related news. Here are some of the biggest stories from my point of view:


            • The Accountable Care Act was signed into law March 23, 2010.  The most significant piece of health legislation since Medicare, the law is projected to expand health insurance coverage to 32 million who are currently uninsured. It aims to achieve this through the creation of state-based health benefit exchanges for individuals and small businesses that promote competition amongst health insurance plans, and through an expansion of Medicaid.  The act will penalize those who do not purchase coverage, it aims to end denials based on pre-existing conditions, and will allow children to be covered under their parents policies until age 26. The legality of the individual mandate to purchase insurance has been called into question. 
            • Why the Mayo Clinic is refusing to see Medicare patients.  As Dr. Toni Brayer points out in her blog: “Medicare, the government insurance company for everyone over age 65 (and for the disabled) pays fees to primary care physicians that guarantee bankruptcy.  Additionally, 70% of hospitals in the United States lose money on Medicare patients. That’s right, for every patient over age 65, it costs the hospital more to deliver care than the government reimburses.”  This problem can only be expected to worsen as Medicare tightens its belt.  The “SGR,” a formula that determines Medicare’s reimbursement rates to physicians, will decrease physician reimbursement by as much as 40 percent in years to come.  A permanent fix to the SGR has been delayed multiple times.  However, the reality is that a permanent fix is needed lest more health care providers will drop Medicare.  
            • Final meaningful use criteria published in July 2010. Beginning in 2011 Medicare and Medicaid will provide significant financial incentives for qualified health providers to adopt and use electronic health records. The final criteria for “meaningful use” qualification were released this year and are discussed in the New England Journal of Medicine by David Blumenthal.  
            • Dabigatran gets FDA approval for treatment of non-valvular atrial fibrillation as an alternative to warfarin. For years warfarin has been the sole option for management of conditions that cause  increased morbidity and mortality related to their clotting risk. A new generation of anticoagulants has emerged and appears to offer multiple advantages over warfarin. 
            • Transcatheter aortic valve replacement is superior to medical therapy for inoperable aortic stenosis. The year’s most important cardiology news,  percutaneous, transcatheter replacement of aortic valves is a new option for high risk patients who are unable to tolerate open-heart surgery. 
            • Early detection of Alzheimer’s Disease. The advent of a new biomarker test that is able to predict, with 100 percent accuracy, asymptomatic individuals who will develop Alzheimer’s Disease. This test has the potential to accurately identify millions of individuals who are at future risk and could be important to the future development of targeted therapeutics. However, widespread use of the test will bring up ethical and cost related dilemmas. 
            • The AMA publishes guidelines for the ethical use of social media by physicians.  Millions use Facebook, Twitter and blogs  to network and transmit information. This year the AMA set forth a policy to help guide the professionalism of physician-users of social media and safeguard the doctor-patient relationship. 
            • The Institute of Medicine questions the practice of high dose vitamin D supplementation.   Vitamin D mania hit the clinics several years back with the finding that a majority of Americans are deficient, and that those with higher levels do better with respect to a number of important health outcomes. However, recently the Institute of Medicine curbed the current enthusiasm for prescribing high dose vitamin D supplementation, citing a paucity of high quality data supporting the safety of this practice. 
            • Lung CT for early detection of lung cancer in high risk patients reduces lung cancer mortality.  Lung cancer continues to be the most common cause of cancer related death in Americans.  A new screening test demonstrates effectiveness in the early detection of lung cancer in those at high risk.  
            • The mammography debate continues.  In November of 2009 the U.S. Preventive Services Task Force revised its mammography recommendations, no longer recommending annual mammography for women ages 40 to 50.  This recommendation made on the eve of health reform, which contradicted the guidelines of other prominent medical societies, sent many into a furor over the appropriate role of “panels,” seen as government-sponsored, in guiding medical decision-making.

              The politics of prevention and screening are likely to continue to make big news in 2011. This year for the first time Medicare will begin to cover an annual wellness exam.  Just last week we learned that a discussion of end-of-life, advance directives would be reimbursed as an element of the annual physical for seniors.  This announcement has rekindled the “death panel” debate.

              The appropriate role and political agendas of expert panels that set policy and guide medical decision-making and reimbursement are likely to continue to stir controversy, particularly as Medicare administrators begin the attempt to rein in cost, while all the while attempting to avoid the accusation of rationing health care.
















              Friday, December 10, 2010

              Changing the Business of Anticoagulation


              The emergence of a new generation of anticoagulants, including the direct thrombin inhibitor, dabigatran and the factor Xa inhibitor, rivaroxaban, has the potential to significantly change the business of thinning blood in the United States. For years warfarin has been the main therapeutic option for patients with health conditions such as atrial fibrillation, venous thrombosis, artificial heart valves and pulmonary embolus, which are associated with excess clotting risk that may cause adverse outcomes, including stroke and death. However, warfarin therapy is fraught with risk and liability.  The drug interacts with food and many drugs and requires careful monitoring of the prothrombin time (PT) and international normalized ratio (INR). 

              Recently, when I applied for credentialing as solo practioner, I was asked by my medical malpractice insurer to detail my protocol for monitoring patients on anticoagulation therapy with warfarin.  When I worked in group practice at the Emory Clinic in Atlanta I referred my patients to Emory’s Anticoagulation Management Service (AMS), which I found to be a wonderful resource.  In fact, “disease management” clinics for anticoagulation are common amongst group practices because of the significant liability issues. Protocol based therapy and dedicated management teams improve outcomes for patients on anticoagulation with warfarin. I spoke with Dr. Donald Davis, Medical Director of the Emory Anticoagulation Management Service, who noted that the AMS was originally established as a service to promote patient safety.  However, it has also proved to be lucrative for Emory Healthcare.  Currently Emory’s AMS has expanded to seven locations in metro Atlanta and cares for 3,400 patients.   Piedmont Hospital, the Atlanta VA Medical Center and Kaiser have similar programs.  Patients on blood thinners come in as often as two to three times monthly for a nurse visit and monitoring of their PT and INR.  A patient of mine on chronic warfarin therapy recently shared his medical bills with me, questioning the high fees he was charged for each of his anticoagulation clinic visits.  Fortunately for him, his health insurance will foot those bills.

              The advantage of the newer drugs, dabigatran and rivaroxaban, is that they do not require laboratory monitoring and do not appear to interact with other drugs and foods.  Dabigatran was recently approved by the FDA based on results of RE-LY,  which compared it to warfarin in patients with atrial fibrillation for prevention of stroke. At a dose of 110 mg twice daily dabigatran had similar efficacy and lower bleeding risk than warfarin. At a higher dose (150mg twice daily) it had superior efficacy and equivalent risk of hemorrhage. For now, dabigatran’s approval is limited to the prevention of stroke in patients with non-valvular atrial fibrillation.  However, the RE-COVER trial compared dabigatran to warfarin in patients with venous thromboembolism.  In this trial the drugs were found to have equivalent efficacy, though dabigatran was found to have a lesser risk of major bleeding.  Dabigatran is currently approved for use in Europe for the prevention of venous thromboembolism in patients undergoing orthopedic surgery.  It has not yet been approved for this indication in the United States. 

              Another blood thinner, the factor Xa inhibitor, rivaroxaban’s efficacy has been demonstrated in the recently published results of the Acute DVT and Continued Treatment Study of the EINSTEIN program. In these trials rivaroxaban therapy was compared with standard therapy for acute DVT with enoxaparin followed by a vitamin K agonist (i.e. warfarin).  Rivaroxaban at an initial dose of 15 mg twice daily and then 20 mg once daily was found to have similar efficacy and risk.  In the Continued Treatment Trial rivaroxaban was compared with placebo and found to reduce the incidence of recurrent thrombotic events and to have an acceptable risk of bleeding. FDA approval of rivaroxaban is still pending.
              There has been significant discussion about the cost of these newly developed drugs. At Publix pharmacy in Atlanta dabigatran runs $271.95 for sixty 150 mg tablets. A recent study published in the Annals of Internal Medicine found the drugs are likely to be cost-effective. After reviewing my patient’s bills from anticoagulation clinic I can attest to the likelihood that the drugs will be cost-effective when taking into account the lab and office visit fees required for monitoring.  However their use will create a shifting of reimbursement away from medical centers (anticoagulation clinics) to the pharmaceutical industry.  If insurers don’t cover the full cost of these drugs consumers could bear more costs.  Health systems, such as the Veterans Administration or Emory Healthcare, that have established anticoagulation programs, may have to reorganize as the need for intense monitoring becomes obsolete.  Will the need for reorganization slow the adoption of new anticoagulants onto hospital formularies? As with any new drug, the long term safety of dabigatran and rivaroxaban has not been proven. In 2006 a direct thrombin inhibitor, ximelagatran, was pulled from the market because it was found to cause liver toxicity. What occurs with anticoagulation adoption and use within the United States could prove to be an interesting example of how economic conflicts of interest drive medical decision-making. 

              Time will tell how the new anticoagulants compare with warfarin in terms of safety and efficacy.   However, it seems likely that economics will be a factor in the way in which these drugs are adopted and used in medical practice. But, let's hope that the primary factor will be the health and quality of life of our patients.

              Tuesday, November 23, 2010

              What’s New in Hypertension with JNC 8 on the Horizon?

              If David Letterman were to make a Top Ten list called: “Things that Doctors do that Really Matter,” treating hypertension would certainly make the cut. Hypertension is highly prevalent within our society, with about one in three U.S. adults affected. The relationship between blood pressure and cardiovascular risk is continuous and independent of other cardiovascular risk factors. Treatment of hypertension has been demonstrated to reduce risk of stroke by 35 to 40 percent and risk of myocardial infarction by 20 to 25 percent. If you are reading this thinking, “but I’ve always had low blood pressure,” here’s some cheerful news: 90 percent of adults who have normal blood pressure at age 55 will develop hypertension as they age. Thus, the detection and appropriate management of elevated blood pressure is one of the most important tasks in the practice of providing primary care to adult patients.


              Those of us who treat hypertension hopefully have heard of the Joint National Committee (JNC) guidelines on hypertension. The latest set, “JNC 7,” came out in 2003. Since 1978, when the National Heart, Lung and Blood Institute (NHLBI) formed its first multidisciplinary panel (JNC 1) to review the evidence and formulate its summary, these guidelines have been the major clinical practice rule set governing appropriate treatment of hypertension. It’s been nearly a decade and JNC 8 is expected to be released in the spring of 2011.

              Recently I had the pleasure of listening to a talk at the Georgia Chapter meeting of the American College of Cardiology by Dr. Keith Ferdinand, Clinical Professor of Medicine, Division of Cardiology at Emory and Chief Science Officer of the Association of Black Cardiologists. Dr. Ferdinand, who has served on previous NHLBI JNC committees reviewed the last decade of data that is likely to impact the newest set of hypertension guidelines.

              Some of my take home points from this talk are listed below:

              • Evidence supports the treatment of hypertension in octogenarians. Patients treated with indapamide (a diuretic) with or without perindopril (an ace inhibitor) had 30% reduced risk of stroke and a 21% reduced risk of death from any cause.
              • The blood pressure treatment goal for diabetic patients may be revised, based on the ACCORD intensive blood pressure lowering trial, to <140/90 (currently <130/80). ACCORD found no cardiovascular benefit for the primary endpoint with more aggressive lowering of blood pressure (to <120 systolic versus <140 systolic) in high risk hypertensive diabetic patients.
              • ACCORD did find a small reduction in a secondary endpoint, total stroke and non-fatal stroke, in study participants treated to the more aggressive blood pressure goal. In addition the placebo group in ACCORD was noted to have on average relatively well controlled blood pressure.
              • The ONTARGET trials found that there is not good evidence to support either renal or cardiovascular benefit from the combined use of ace inhibitors with ARBs for high risk patients. These randomized controlled trials looked at ramipril, telmasartan, and their combined use with respect to renal and cardiovascular outcomes.
              • In refractory hypertensive patients, spironolactone 25 mg should be considered as an additional agent.
              • Amongst the class of thiazide diuretics there may be differences amongst agents and their prescribed dosages in terms of efficacy for cardiovascular risk reduction. The longer acting chlorthalidone may be more effective than the shorter acting hydrochlorothiazide. Some of the most widely cited studies providing evidence for the use of thiazides as first line treatment for hypertension are based on study of chlorthalidone or using higher doses of HCTZ (50mg) than those normally prescribed.
              • The combination of ace inhibitor (benazepril) and dihydropyridine calcium channel blockers (amlodipine) may be superior to the ace inhibitor and diuretic (hydrochlorothiazide) combination for hypertension treatment (ACCOMPLISH).
              • Atenolol is falling out of favor, with a relative lack of evidence supporting its use as a first line therapy for hypertension. More attention is likely to be given to beta blocker selection on the basis of demonstrated cardiovascular outcomes (metoprolol, carvedilol) in JNC 8.
              As a primary care physician I found it very useful to hear Dr. Ferdinand’s opinion about what’s to come with respect to JNC 8’s hypertension guidelines. I already will be changing some of my practice based on this knowledge. I look forward to reading the guidelines and hearing the reaction of experts in the spring of 2011. It appears as though with hypertension, as with other fields of medicine, there will be a growing emphasis on specific drug and dose selection as opposed to class of drug selection.